Your browser doesn't support javascript.
loading
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin; Dust, Sofia; Stover, Daniel G; Chi, David; Primack, Benjamin; Cao, Shiliang; Bernhardy, Andrea J; Coulson, Rhiannon; Lazaro, Jean-Bernard; Kochupurakkal, Bose; Sun, Heather; Unitt, Christine; Moreau, Lisa A; Sarosiek, Kristopher A; Scaltriti, Maurizio; Juric, Dejan; Baselga, José; Richardson, Andrea L; Rodig, Scott J; D'Andrea, Alan D; Balmaña, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; Shapiro, Geoffrey I.
Affiliation
  • Johnson SF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Cruz C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain; Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain.
  • Greifenberg AK; Department of Structural Immunology, Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany; Group Physical Biochemistry, Center of Advanced European Studies and Research, 53175 Bonn, Germany.
  • Dust S; Department of Structural Immunology, Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany; Group Physical Biochemistry, Center of Advanced European Studies and Research, 53175 Bonn, Germany.
  • Stover DG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Chi D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Primack B; Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Cao S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Bernhardy AJ; Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • Coulson R; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent's Health Network, Darlinghurst, NSW 2010, Australia.
  • Lazaro JB; Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
  • Kochupurakkal B; Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
  • Sun H; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Unitt C; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Moreau LA; Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Sarosiek KA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Scaltriti M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Juric D; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
  • Baselga J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Richardson AL; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Rodig SJ; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • D'Andrea AD; Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Balmaña J; Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain.
  • Johnson N; Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • Geyer M; Department of Structural Immunology, Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany; Group Physical Biochemistry, Center of Advanced European Studies and Research, 53175 Bonn, Germany.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Lim E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent's Health Network, Darlinghurst, NSW 2010, Australia. Electronic address: e.lim@garvan.org.au.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: geoffrey_shapiro@dfci.harvard.edu.
Cell Rep ; 17(9): 2367-2381, 2016 11 22.
Article in En | MEDLINE | ID: mdl-27880910
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cyclin-Dependent Kinases / Drug Resistance, Neoplasm / BRCA1 Protein / Triple Negative Breast Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors / Mutation Limits: Animals / Female / Humans Language: En Journal: Cell Rep Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cyclin-Dependent Kinases / Drug Resistance, Neoplasm / BRCA1 Protein / Triple Negative Breast Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors / Mutation Limits: Animals / Female / Humans Language: En Journal: Cell Rep Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States